Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
2025-06-16 16:14:20 ET
Thesis Overview
Lyra therapeutics ( LYRA ) is developing corticosteroid-eluting implants for treatment of chronic rhinosinusitis; LYR-210 for patients without prior surgery and LYR-220 for patients with prior ethmoid sinus surgery. A single therapy (easily placed at the ENT's office) provides a 6-month duration of treatment. At the time of writing, the stock is down by >90% since announcing failure of its first ph3 trial, ENLIGHTEN 1. LYRA had some good explanations on why this happened and decided to continue further development, awaiting results of its 2nd phase 3, ENLIGHTEN 2. To the market's surprise, LYRA recently announced that ENLIGHTEN 2 met both the primary endpoint as well as clinically meaningful secondary endpoints (resulting in considerable upside for my portfolio having bought the dip). I have personally locked in profits following the spike after the news, but I have started re-establishing a position....
Read the full article on Seeking Alpha
For further details see:
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
NASDAQ: LYRA
LYRA Trading
-0.75% G/L:
$1.32 Last:
2,591 Volume:
$1.32 Open:
